DOPTELET SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOPTELET SPRINKLE (DOPTELET SPRINKLE).
DOPTELET (avatrombopag) is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor on megakaryocytes and megakaryocyte precursor cells, leading to differentiation, proliferation, and increased platelet production.
| Metabolism | Primarily metabolized by CYP2C9 and CYP3A4; parent drug and metabolites are eliminated in feces (59%) and urine (31%) with minimal renal excretion of unchanged drug. |
| Excretion | Fecal (approx. 59%), renal (approx. 31%) as unchanged drug and metabolites |
| Half-life | Terminal half-life approximately 31-35 hours; supports once-daily dosing |
| Protein binding | Approximately 96% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Approximately 0.49 L/kg (range 0.38-0.58 L/kg); indicates distribution into total body water |
| Bioavailability | Oral bioavailability approximately 63% (fasting conditions) |
| Onset of Action | Increase in platelet count observed within 5-7 days after starting oral administration |
| Duration of Action | Platelet count elevation persists for approximately 2 weeks after discontinuation, with return to baseline within 3 weeks |
10 mg (5 capsules) orally once daily for 5 consecutive days. Two to 4 hours before planned procedure, total dose should be taken 5 days prior to the procedure.
| Dosage form | GRANULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m²). For severe renal impairment (eGFR <30 mL/min/1.73m²) or dialysis, limited data; use with caution. |
| Liver impairment | Child-Pugh A: No dose adjustment. Child-Pugh B: 10 mg once daily for 5 days; monitor closely. Child-Pugh C: Not recommended (no data). |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No recommended dosing. |
| Geriatric use | No specific dose adjustment in elderly (≥65 years) based on pharmacokinetics; clinical experience limited. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOPTELET SPRINKLE (DOPTELET SPRINKLE).
| Breastfeeding | Unknown if avatrombopag is excreted in human milk. M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, breast-feeding should be discontinued during treatment or treatment should be discontinued taking into account importance to mother. |
| Teratogenic Risk | Pregnancy Category N (no data). Avatrombopag is not absorbed systemically due to its SPRINKLE formulation, but minimal systemic exposure cannot be excluded. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at exposures up to 3 times the human clinical exposure. Fetal risk cannot be ruled out; use only if clearly needed. |
■ FDA Black Box Warning
Risk of thrombotic complications, including portal vein thrombosis in patients with chronic liver disease; thrombotic events (arterial and venous) have been reported in patients with ITP.
| Serious Effects |
History of thrombotic events (e.g., venous thromboembolism, arterial thrombosis) in patients with ITP; known hypersensitivity to avatrombopag or any excipients.
| Precautions | Thrombotic/thromboembolic complications; hepatotoxicity and hepatic decompensation in chronic liver disease; bone marrow reticulin formation and risk for progression to myelofibrosis; need for monitoring of platelet counts; should not be used to normalize platelet counts in patients with chronic liver disease. |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests and platelet count regularly. Fetal monitoring per standard obstetric care; no specific fetal monitoring required. |
| Fertility Effects | No human data. In animal studies, no effects on fertility or reproductive performance were observed at exposures up to 3 times the human clinical exposure. Clinical significance unknown. |